Mark Christopher Benyunes MD
Biotechnology at Genentech, Inc. Sr. Group Medical Director Genentech
Join to View Full Profile
1 DNA WayMailstop 444BSouth San Francisco, CA 94080
Phone+1 650-225-1628
Dr. Benyunes is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 1989 - 1992
Johns Hopkins UniversityResidency, Internal Medicine, 1985 - 1987- Johns Hopkins UniversityInternship, Internal Medicine, 1984 - 1985
Duke University School of MedicineClass of 1984
Certifications & Licensure
WA State Medical License 1989 - 2023
NC State Medical License 1987 - 1990
GA State Medical License 1989 - 1989
SC State Medical License 1989 - 1989
AL State Medical License 1988 - 1988
IA State Medical License 1988 - 1988
WV State Medical License 1988 - 1988
American Board of Internal Medicine Internal Medicine- Join now to see all
Publications & Presentations
PubMed
- 15 citationsSubcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety studySherko Kuemmel, Carlo Tondini, Jacinta Abraham, Zbigniew Nowecki, Bartosz Itrych
Breast Cancer Research and Treatment. 2021-03-21 - 467 citationsPertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled...Sandra M Swain, David Miles, Sung Bae Kim, Young-Hyuck Im, Seock-Ah Im
The Lancet. Oncology. 2020-04-01 - 885 citationsAdjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast CancerGunter von Minckwitz, Marion Procter, Evandro de Azambuja, Dimitrios Zardavas, Mark C. Benyunes
The New England Journal of Medicine. 2017-06-05
Authored Content
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast CancerJuly 2017
Grant Support
- Immunotherapy After Bone Marrow TransplantationNational Cancer Institute1992
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
